The main objective of the study was to investigate the efficacy of using a mono and combined therapy drugs Impaza and Nebido for secondary prevention and treatment of ED. It was examined 79 diabetic patients with ED. The age of patients within 18-60 years, duration of diabetes - from 6 months to 29 years, ED - from 6 months to 12 years. To identify the ED was used International index of erectile function (IIEF). The patients were divided into 3 groups: I - patients with organic ED, II - with psychogenic ED and III group - with mixed ED. Drags Impaza and Nebido used in all three groups, as mono or as complex therapy. It was using routine (anamnesis, clinico- biochemical data) and special (pharmacodopplerography) methods of study. The study did not include patients with increased level of prostate-specific antigen (PSA), polycythemia, obstruction of the urinary tract with the prostate size increasing and prostate cancer. Statistical data was studed by using Pearson's χ2-test. The results showed the following. Indicators of glycohemoglobin above normal reduces the effectiveness of the treatment of erectile dysfunction in patients with diabetes mellitus.The combined use of drugs Impaza and Nebido in patients with ED had a positive resultes in 41,4-91,7% of the cases. These drugs are effective in diabetic patients with mild and moderate form of erectile dysfunction.